Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Period, Open Label, Phase 1 Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects

NCT04018950 is registered in ClinicalTrials.gov with Entasis Therapeutics as lead sponsor.

NCT NCT04018950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04018950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Period, Open Label, Phase 1 Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects
Lead sponsor
Entasis Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
June 21, 2019
Completion date
July 26, 2019
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acinetobacter baumannii-calcoaceticus complex infections